GlassScriptPhysician profile
John R Browning
NPI 1396185765
$1,171.22
in general payments reported to CMS, 2019-2025
20 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.82 · 2020: $137 · 2022: $184 · 2023: $436 · 2024: $190 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $165.84 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $129.32 | 2019-2023 | Rybelsus, Ozempic |
| Abbott Laboratories | $125.21 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $111.89 | 2020-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $87.55 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $72.54 | 2019-2025 | |
| Abbvie INC. | $58.03 | 2023-2024 | Ubrelvy, Viberzi, Linzess |
| Teva Pharmaceuticals USA, INC. | $54.66 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $54.15 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $48.32 | 2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.56 | 2023-2024 | Ofev |
| Mylan Specialty L.P. | $34.90 | 2022 | |
| Nestle Healthcare Nutrition INC. | $32.57 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $31.71 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $30.24 | 2020-2025 | Airsupra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $18.81 | 2020 | |
| Esperion Therapeutics, INC. | $17.05 | 2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $14.46 | 2022 | |
| Hologic Sales and Service, LLC | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.